Dementia Today.net

Site updated at Wednesday, 22 June 2016

Living with Dementia

Cognitive Dysfunction

Cognition and Cognitive Testing

As noted above, the diagnoses of mild cognitive impairment and dementia of the Alzheimer type both require the presence of memory impairment. To distinguish between MCI and DAT, it is important to determine the degree and course of memory impairment, the presence or absence of additional domains of cognitive dysfunction, and the impact of… Cognition and Cognitive Testing   



Nutritional intervention helps in mild Alzheimer’s disease

A second clinical trial of the medical food Souvenaid confirmed that daily intake of the nutritional intervention improves memory in people with mild Alzheimer’s disease (AD). Results of the trial - called Souvenir II - were presented at the 4th International Conference on Clinical Trials in Alzheimer’s Disease (CTAD) in San Diego, California on… Nutritional intervention helps in mild Alzheimer’s disease   



No Benefit for Dimebon in Huntington’s

An antihistamine that failed to work in Alzheimer’s disease also fell short of expectations in Huntington’s disease, researchers reported.

In a randomized controlled trial, latrepirdine (Dimebon) didn’t improve cognition or global function compared with placebo, Ray Dorsey, MD, of Johns Hopkins, and colleagues reported online in the Archives of Neurology.

Currently, medications can mitigate… No Benefit for Dimebon in Huntington’s   



New mouse model could revolutionize research in Alzheimer’s disease

Alzheimer’s disease, the primary cause of dementia in the elderly, imposes a tremendous social and economic burden on modern society. In Japan, the burden of the disease in 2050 is estimated to be a half a trillion US dollars, a figure equivalent to the government’s annual revenues.

Unfortunately, it has proven very difficult to… New mouse model could revolutionize research in Alzheimer’s disease   



Alzheimer’s Disease

insulin-like growth factor-11 - high-dose chemotherapy1 - body mass index2 - dsm-51 - phosphorylated tau1 - senile atrophy and aphasia1 - moderate dementia1 - type of dementia4 - alzheimer's and parkinson's diseases1 - alzheimer's-like tau tangles1 - synthetic tau fibrils1 - ftd1 - parkinson's disease risk1 - living with dementia1 - coronary heart disease1 - dementia-related diseases1 - apoplectic dementia1 - overweight1 - penn medicine1 - medical history1 - progressive dementia3 - early alzheimer's damage1 - alzheimer's society2 - stiffness2 - university of california2 - quality of care2 - alzheimer's agitation1 - deep brain stimulation2 - haldol1 - prevention of delirium1 -